Home Study Modules
Pharmacist Administration of Long-Acting Injectable Maintenance Medications: Understanding the Regulations
This module reviews the regulations and policies for pharmacist administration of long-acting maintenance medications.
Learning Objectives:
At the completion of this knowledge-based activity, learners should be able to:
- Describe the current regulations for pharmacist administration of long-acting injectable medications in Maryland.
- Outline the training requirements for pharmacist administration of long-acting injectable medications in the State of Maryland.
- Describe examples of documentation utilized in pharmacist administration of long-acting injectable medications.
- Review example policies utilized in pharmacist administration of long-acting injectable medications.
UAN: 0025-0000-23-065-H03-P
CE Credit: 1.0 Contact Hours
Instructor:
Megan Ehret, PharmD, MS, BCPP
Professor
Co-Director of the Mental Health Program
University of Maryland School of Pharmacy
Dr. Megan Ehret, planner and author/presenter for this activity, participated in a focus group on a Peer to Peer Summit on unbranded LAI use with Janssen Pharmaceuticals and served on the consumer council which provides insights into LAI use in an unbranded fashion for Otsuka Pharmaceuticals. All financial relationships have been mitigated.
Maryland Pharmacist Opioid Use Disorder (OUD) LAI Administration Training
This module reviews the management of a patient population with opioid use disorder and the long-acting injectable medications utilized in the treatment of opioid use disorder.
Learning Objectives:
At the completion of this knowledge-based activity, learners should be able to:
- Describe the management of a patient population with opioid use disorder, including current treatment guidelines
- List current long-acting injectable medication(s) utilized in the treatment of opioid use disorder
- Outline pharmacokinetics, significant drug interactions, warnings/precautions, and adverse effects for long-acting injectable medication(s) for the treatment of opioid use disorder
- Describe the dosing and administration frequency of the long-acting injectable medication(s) for the treatment of opioid use disorder
UAN: 0025-0000-23-066-H01-P
CE Credit: 1.0 Contact Hours
Instructor:
Bethany DiPaula, PharmD, BCPP
Professor
Co-Director of the Mental Health Program
University of Maryland School of Pharmacy
Dr. DiPaula, presenter for this activity, has no financial relationships to disclose.
Long-Acting Injectable Medications for the Treatment of Schizophrenia and Bipolar Disorder
This module reviews the management of a patient population with opioid use disorder and the long-acting injectable medications utilized in the treatment of schizophrenia and bipolar disorder.
Learning Objectives:
At the completion of this knowledge-based activity, learners should be able to:
- Describe the management of a patient population with schizophrenia or bipolar disorder, including treatment guidelines
- List the current long-acting injectable medications utilized in the treatment of schizophrenia or bipolar disorder
- Outline the pharmacokinetic, significant drug interactions, warnings/precautions, and adverse effects for the long-acting injectable medications for the treatment of schizophrenia or bipolar disorder
- Describe the dosing and administration frequency of the long-acting injectable medications for the treatment of schizophrenia or bipolar disorder
UAN: 0025-0000-23-067-H01-P
CE Credit: 2.0 Contact Hours
Instructor:
Megan Ehret, PharmD, MS, BCPP
Professor
Co-Director of the Mental Health Program
University of Maryland School of Pharmacy
Dr. Megan Ehret, planner and author/presenter for this activity, participated in a focus group on a Peer to Peer Summit on unbranded LAI use with Janssen Pharmaceuticals and served on the consumer council which provides insights into LAI use in an unbranded fashion for Otsuka Pharmaceuticals. All financial relationships have been mitigated.
Long-acting Antiretroviral Therapies
This module reviews the management of a patient population with opioid use disorder and the long-acting injectable medications utilized in the treatment of HIV.
Learning Objectives:
At the completion of this knowledge-based activity, learners should be able to:
- Describe the management of a patient population with HIV, including treatment guidelines
- List the current long-acting injectable medications utilized in the treatment/prevention of HIV
- Outline the pharmacokinetic, significant drug interactions, warnings/precautions, and adverse effects for the long-acting injectable medications for the treatment/prevention of HIV
- Describe the dosing and administration frequency of the long-acting injectable medications for the treatment/prevention of HIV
UAN: 0025-0000-23-068-H02-P
CE Credit: 1.0 Contact Hours
Instructor:
Neha Pandit, PharmD, BCPS
Professor
University of Maryland School of Pharmacy
Dr. Pandit, author and presenter for this activity, has received a research grant from Thera Technologies. All financial relationships for Dr. Pandit have been mitigated.
Pharmacologic Interventions for Transgender/Non-binary Adolescents and Adults
This module reviews the the goals of transgender care and the long-acting injectable medications utilized for puberty suppression and GAHT.
Learning Objectives:
At the completion of this knowledge-based activity, learners should be able to:
- Recognize the goals of transgender care management at different transitional stages
- Classify which pharmacologic agents are indicated for use at different stages, particularly long-acting injectable formulations
- Contrast the different dosing and administration preparations for long-acting injectable puberty suppression and GAHT
- Identify important monitoring parameters and medication related variables for a given pharmacologic intervention
UAN: 0025-0000-23-069-H01-P
CE Credit: 1.0 Contact Hours
Instructor:
Amy Kruger Howard, MS, PharmD
Pediatric Clinical Pharmacist
University of Maryland School of Pharmacy
Dr. Amy Kruger Howard, presenter for this activity, has no financial relationships to disclose.
Long-Acting Maintenance Medication Administration Techniques
This module reviews the various injection techniques and locations for long-acting injectables.
Learning Objectives:
At the completion of this knowledge-based activity, learners should be able to:
- Identify routes of administration for long-acting maintenance injections administered by a pharmacist
- Describe appropriate injection technique for intramuscular and subcutaneous injections
- Describe how to give a medication via z-track administration
- Review volumes of injection for various injection routes
UAN: 0025-0000-23-070-H99-P
CE Credit: 1.0 Contact Hours
Instructor:
Megan Ehret, PharmD, MS, BCPP
Professor
Co-Director of the Mental Health Program
University of Maryland School of Pharmacy
Dr. Megan Ehret, planner and author/presenter for this activity, participated in a focus group on a Peer to Peer Summit on unbranded LAI use with Janssen Pharmaceuticals and served on the consumer council which provides insights into LAI use in an unbranded fashion for Otsuka Pharmaceuticals. All financial relationships have been mitigated.
Initial Release (all home study modules): May 22, 2023
Expiration Date (all home study modules): May 22, 2024
Criteria for Successful Completion for Home Study Modules
To successfully complete a module, learners must complete all activity components including the audiovisual presentations, active learning exercises, a post-test, and activity evaluation. Participants must receive a score of at least 70% on each post-test to receive credit. A post-test may be taken up to three (3) times. A link to the evaluation will be available once learners have successfully completed all other course segments. Statements of CE Credit will be available electronically via CPE Monitor within sixty (60) days of completion of the activity.
The University of Maryland School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Privacy and Confidentiality: The University of Maryland School of Pharmacy is committed to protecting the privacy of our learners. All enrollees are protected under The Family Educational Rights and Privacy Act (20 U.S.C. § 1232g; 34 CFR Part 99) (FERPA). The UMB Policy on Confidentiality and Disclosure of Student Records can be found at: https://www.umaryland.edu/policies-and-procedures/library/academic-affairs/policies/iii-630a.php.
In order to submit your continuing education credit record to National Association of Boards of Pharmacy (NABP) CPE Monitor, we must collect personal information including, but not limited to, name, NABP ID, and date of birth. Additionally, Maryland-licensed pharmacists seeking a Contraceptive Prescribing credential must allow for submission of their activity completion record to the Maryland Board of Pharmacy.
Copyright: Resources are provided for the educational benefit of our learners and are not for distribution. All information and materials provided are the property of and have been prepared by the University of Maryland Baltimore or have been granted permission for use by the copyright owner. No portion of this module may be reproduced or transmitted without written permission. All rights reserved.
Statement on the use of images/videos:
SMI Adviser, a center for excellence for treatment of serious mental illness, is funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) and administered by the American Psychiatric Association (APA). SMI Adviser has created a series of videos on the proper preparation and administration of long-acting injectable medications. They have granted approval for use of their videos in our training program.
Use of Trade Names: The trade names of the drugs and delivery systems in this module are for the purpose of product identification only. This activity does not intend to imply endorsement for any commercial products discussed.